Table 4. Graft-versus-host disease in... | American Society of Hematology

Table 4.

Graft-versus-host disease in patients given or not given methylprednisolone

	Treatment group		Pvalue^4-150
	MP+	MP−	Pvalue^4-150
Acute GVHD, all patients	10/53 (19%)	31/55 (56%)	.0001
Grade I	3	11
Grade II	4	11
Grade III	1	5
Grade IV	2	4
Grade II-IV	7 (13%)	20 (36%)	.005
Acute GVHD, low-risk^4-151patients	5/33 (15%)	21/37 (57%)	.0004
Grade I	3	8
Grade II	1	9
Grade III	0	3
Grade IV	1	1
Grade II-IV	2 (6%)	13 (35%)	.003
Chronic GVHD, all patients^‡	18/50 (36%)	25/52 (48%)	.17
Limited	12	16
Extensive	6	9
Chronic GVHD, low-risk patients^‡	10/33 (30%)	19/37 (51%)	.06
Limited	8	13
Extensive	2	6

	Treatment group		Pvalue^4-150
	MP+	MP−	Pvalue^4-150
Acute GVHD, all patients	10/53 (19%)	31/55 (56%)	.0001
Grade I	3	11
Grade II	4	11
Grade III	1	5
Grade IV	2	4
Grade II-IV	7 (13%)	20 (36%)	.005
Acute GVHD, low-risk^4-151patients	5/33 (15%)	21/37 (57%)	.0004
Grade I	3	8
Grade II	1	9
Grade III	0	3
Grade IV	1	1
Grade II-IV	2 (6%)	13 (35%)	.003
Chronic GVHD, all patients^‡	18/50 (36%)	25/52 (48%)	.17
Limited	12	16
Extensive	6	9
Chronic GVHD, low-risk patients^‡	10/33 (30%)	19/37 (51%)	.06
Limited	8	13
Extensive	2	6

Significance of the difference in cumulative incidence.

See Table 1.

At risk for at least 100 days.